Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

Compare

389 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EWTX Analyst Ratings

Strong Buy

9 Buy

2 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Edgewise

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EWTX Stock 12 Month Forecast

Average Price Target

$39.27

▲(188.54%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Edgewise Therapeutics in the last 3 months. The average price target is $39.27 with a high forecast of $51.00 and a low forecast of $14.00. The average price target represents a 188.54% change from the last price of $13.61.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","52":"$52","21.25":"$21.3","31.5":"$31.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21.25,31.5,41.75,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.82,15.756923076923076,18.693846153846152,21.630769230769232,24.567692307692308,27.504615384615384,30.441538461538464,33.378461538461536,36.315384615384616,39.252307692307696,42.18923076923077,45.12615384615385,48.06307692307693,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.82,14.854615384615386,16.88923076923077,18.923846153846156,20.958461538461542,22.993076923076927,25.02769230769231,27.062307692307694,29.09692307692308,31.131538461538465,33.16615384615385,35.20076923076924,37.23538461538462,{"y":39.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.82,12.910769230769231,13.001538461538463,13.092307692307692,13.183076923076923,13.273846153846154,13.364615384615385,13.455384615384615,13.546153846153846,13.636923076923077,13.727692307692308,13.818461538461538,13.909230769230769,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.38,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$51.00

Average Price Target$39.27

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Martin AusterRaymond James

Raymond James

$46

Buy

237.99%

Upside

Initiated

07/29/25

Edgewise Therapeutics initiated with a Strong Buy at Raymond JamesEdgewise Therapeutics initiated with a Strong Buy at Raymond James

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$42

Buy

208.60%

Upside

Initiated

06/30/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joseph SchwartzLeerink Partners

Leerink Partners

$50

Buy

267.38%

Upside

Reiterated

06/27/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Edgewise Therapeutics (NASDAQ: EWTX) and Arcturus Therapeutics (NASDAQ: ARCT)

Laura ChicoWedbush

Wedbush

$40→$35

Buy

157.16%

Upside

Reiterated

06/27/25

Edgewise Therapeutics price target lowered to $35 from $40 at WedbushEdgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Louise ChenScotiabank

Scotiabank

$14

Hold

2.87%

Upside

Reiterated

06/27/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Edgewise Therapeutics (NASDAQ: EWTX)

Leonid TimashevRBC Capital

RBC Capital

$48

Buy

252.68%

Upside

Reiterated

06/26/25

RBC Capital Remains a Buy on Edgewise Therapeutics (EWTX)

James CondulisStifel Nicolaus

Stifel Nicolaus

$16

Hold

17.56%

Upside

Reiterated

06/26/25

Stifel Nicolaus Keeps Their Hold Rating on Edgewise Therapeutics (EWTX)

Srikripa DevarakondaTruist Financial

Truist Financial

$50

Buy

267.38%

Upside

Reiterated

06/26/25

Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges

Yasmeen RahimiPiper Sandler

Piper Sandler

$51

Buy

274.72%

Upside

Reiterated

06/11/25

Analysts' Top Healthcare Picks: Edgewise Therapeutics (EWTX), Insmed (INSM)

Tessa RomeroJ.P. Morgan

J.P. Morgan

$45→$40

Buy

193.90%

Upside

Reiterated

05/16/25

Edgewise Therapeutics (EWTX) PT Lowered to $40 at JPMorganJPMorgan analyst Tessa Romero lowered the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $40.00 (from $45.00) while maintaining a Overweight rating.

Cory KasimovEvercore ISI

Evercore ISI

$50→$40

Buy

193.90%

Upside

Reiterated

05/09/25

Evercore ISI Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)

Debjit ChattopadhyayGuggenheim

Guggenheim

$41

Buy

201.25%

Upside

Initiated

04/30/25

Edgewise a new buy at Guggenheim on two pipeline prospectsGuggenheim has initiated Edgewise Therapeutics ( NASDAQ: ) at buy citing two pipeline candidates in mid-to-late stage development that could be potential blockbusters.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Martin AusterRaymond James

Raymond James

$46

Buy

237.99%

Upside

Initiated

07/29/25

Edgewise Therapeutics initiated with a Strong Buy at Raymond JamesEdgewise Therapeutics initiated with a Strong Buy at Raymond James

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$42

Buy

208.60%

Upside

Initiated

06/30/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joseph SchwartzLeerink Partners

Leerink Partners

$50

Buy

267.38%

Upside

Reiterated

06/27/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Edgewise Therapeutics (NASDAQ: EWTX) and Arcturus Therapeutics (NASDAQ: ARCT)

Laura ChicoWedbush

Wedbush

$40→$35

Buy

157.16%

Upside

Reiterated

06/27/25

Edgewise Therapeutics price target lowered to $35 from $40 at WedbushEdgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Louise ChenScotiabank

Scotiabank

$14

Hold

2.87%

Upside

Reiterated

06/27/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Edgewise Therapeutics (NASDAQ: EWTX)

Leonid TimashevRBC Capital

RBC Capital

$48

Buy

252.68%

Upside

Reiterated

06/26/25

RBC Capital Remains a Buy on Edgewise Therapeutics (EWTX)

James CondulisStifel Nicolaus

Stifel Nicolaus

$16

Hold

17.56%

Upside

Reiterated

06/26/25

Stifel Nicolaus Keeps Their Hold Rating on Edgewise Therapeutics (EWTX)

Srikripa DevarakondaTruist Financial

Truist Financial

$50

Buy

267.38%

Upside

Reiterated

06/26/25

Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges

Yasmeen RahimiPiper Sandler

Piper Sandler

$51

Buy

274.72%

Upside

Reiterated

06/11/25

Analysts' Top Healthcare Picks: Edgewise Therapeutics (EWTX), Insmed (INSM)

Tessa RomeroJ.P. Morgan

J.P. Morgan

$45→$40

Buy

193.90%

Upside

Reiterated

05/16/25

Cory KasimovEvercore ISI

Evercore ISI

$50→$40

Buy

193.90%

Upside

Reiterated

05/09/25

Evercore ISI Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)

Debjit ChattopadhyayGuggenheim

Guggenheim

$41

Buy

201.25%

Upside

Initiated

04/30/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edgewise Therapeutics

1 Month

xxx

Success Rate

11/16 ratings generated profit

Average Return

+1.64%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +1.64% per trade.

3 Months

xxx

Success Rate

10/16 ratings generated profit

Average Return

+30.90%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +30.90% per trade.

1 Year

Laura ChicoWedbush

Success Rate

8/16 ratings generated profit

Average Return

+73.38%

reiterated a buy rating last month

Copying Laura Chico's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +73.38% per trade.

2 Years

xxx

Success Rate

14/26 ratings generated profit

Average Return

+57.05%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of +57.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EWTX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EWTX has received 14 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. EWTX average Analyst price target in the past 3 months is 39.27.

Each month's total comprises the sum of three months' worth of ratings.

EWTX Financial Forecast

EWTX Earnings Forecast

Next quarter’s earnings estimate for EWTX is -$0.41 with a range of -$0.48 to -$0.38. The previous quarter’s EPS was -$0.43. EWTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year EWTX has Preformed in-line its overall industry.

No data currently available

EWTX Sales Forecast

Next quarter’s sales forecast for EWTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. EWTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year EWTX has Preformed in-line its overall industry.

EWTX Stock Forecast FAQ

What is EWTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Edgewise Therapeutics, Inc.’s 12-month average price target is 39.27.

What is EWTX’s upside potential, based on the analysts’ average price target?

Edgewise Therapeutics, Inc. has 188.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EWTX a Buy, Sell or Hold?

Edgewise Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.

What is Edgewise Therapeutics, Inc.’s price target?

The average price target for Edgewise Therapeutics, Inc. is 39.27. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $51.00 ,the lowest forecast is $14.00. The average price target represents 188.54% Increase from the current price of $13.61.

What do analysts say about Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of EWTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

EWTX Analyst Ratings

EWTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edgewise Therapeutics

EWTX Analyst Recommendation Trends

EWTX Financial Forecast

EWTX Earnings Forecast

EWTX Sales Forecast

EWTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts